Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Current Deferred Revenue (2016 - 2017)

Aptevo Therapeutics' Current Deferred Revenue history spans 3 years, with the latest figure at $3.7 million for Q3 2017.

  • For Q3 2017, Current Deferred Revenue rose 478.12% year-over-year to $3.7 million; the TTM value through Sep 2017 reached $3.7 million, up 478.12%, while the annual FY2016 figure was $811000.0, 78.9% down from the prior year.
  • Current Deferred Revenue for Q3 2017 was $3.7 million at Aptevo Therapeutics, up from $1.4 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $3.8 million in Q4 2015 and bottomed at $394000.0 in Q2 2016.
  • The 3-year median for Current Deferred Revenue is $878000.0 (2017), against an average of $1.7 million.
  • The largest annual shift saw Current Deferred Revenue plummeted 78.9% in 2016 before it soared 478.12% in 2017.
  • A 3-year view of Current Deferred Revenue shows it stood at $3.8 million in 2015, then tumbled by 78.9% to $811000.0 in 2016, then surged by 356.23% to $3.7 million in 2017.
  • Per Business Quant, the three most recent readings for APVO's Current Deferred Revenue are $3.7 million (Q3 2017), $1.4 million (Q2 2017), and $878000.0 (Q1 2017).